13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK7684-001

    Acronym: 

    MK7684

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase 1 trial of MK-7684 as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumours.

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid tumours
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase I trial of MK-7684 as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumours.

    Lay Summary

    A Phase 1 trial of MK-7684 as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumours.

    Sponsor / Cooperative group

    Merck

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting